Today the United States has three COVID-19 vaccine candidates in phase 3 trials, as AstraZeneca launched the final stage of a trial of its vaccine candidate, which it plans to test in 30,000 healthy adults.The AstraZeneca vaccine, developed at Oxford University, is already in a phase 3 trial in the United Kingdom.
The first US volunteers were inoculated today at the University of Wisconsin School of Medicine and Public Health in Madison, and AstraZeneca plans to add 50 participants each day after Sep 7.In addition to the AstraZeneca vaccine, Moderna’s vaccine candidate is already in phase 3 trials in the United States, as is Pfizer and BioNTech's.